PMID- 37524416
OWN - NLM
STAT- MEDLINE
DCOM- 20231005
LR  - 20240426
IS  - 1473-4893 (Electronic)
IS  - 1470-2118 (Print)
IS  - 1470-2118 (Linking)
VI  - 23
IP  - 4
DP  - 2023 Jul
TI  - Future therapies for obesity.
PG  - 337-346
LID - 10.7861/clinmed.2023-0144 [doi]
AB  - Obesity is a chronic disease associated with increased morbidity and mortality. 
      Bariatric surgery can lead to sustained long-term weight loss (WL) and 
      improvement in multiple obesity-related complications, but it is not scalable at 
      the population level. Over the past few years, gut hormone-based 
      pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly 
      evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut 
      hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and 
      amylin) as dual or triple agonists are under investigation to enhance and 
      complement the effects of GLP1 on WL and obesity-related complications. 
      Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity 
      pharmacotherapy in which a combination of gut hormones could approach the WL 
      achieved with bariatric surgery. In this review, we discuss emerging obesity 
      treatments with a focus on gut hormone combinations and the concept of a 
      multimodal approach for obesity management.
CI  - (c) Royal College of Physicians 2023. All rights reserved.
FAU - Melson, Eka
AU  - Melson E
AD  - Diabetes Research Centre, Leicester General Hospital, University of Leicester, 
      Leicester, UK.
FAU - Miras, Alexander Dimitri
AU  - Miras AD
AD  - School of Medicine, University of Ulster, Ulster, UK.
FAU - Papamargaritis, Dimitris
AU  - Papamargaritis D
AD  - Kettering General Hospital NHS Foundation Trust, Kettering, UK and associate 
      professor in diabetes and endocrinology, Diabetes Research Centre, Leicester 
      General Hospital, University of Leicester, Leicester, UK dp421@leicester.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Clin Med (Lond)
JT  - Clinical medicine (London, England)
JID - 101092853
RN  - 0 (Gastrointestinal Hormones)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Gastrointestinal Hormones/pharmacology/therapeutic use
MH  - Glucagon-Like Peptide 1/pharmacology/therapeutic use
MH  - Obesity/therapy
MH  - *Bariatric Surgery
MH  - Weight Loss
PMC - PMC10541050
OTO - NOTNLM
OT  - gut hormones
OT  - obesity
OT  - pharmacotherapy
OT  - tirzepatide
COIS- EM declares no conflict of interest. ADM has received grants or contracts from 
      Fractyl, Novo Nordisk and Randox, and payment or honoraria for lectures, 
      presentations, speakers bureaus, manuscript writing or educational events from 
      Novo Nordisk, AstraZeneca, Currax and Boehringer Ingelheim. DP has acted as a 
      speaker for Novo Nordisk and has received grants from Novo Nordisk, Novo Nordisk 
      UK Research Foundation, Academy of Medical Sciences/Diabetes UK and Health 
      Education East Midlands.
EDAT- 2023/08/01 01:08
MHDA- 2023/10/05 06:44
PMCR- 2023/07/01
CRDT- 2023/07/31 20:42
PHST- 2023/10/05 06:44 [medline]
PHST- 2023/08/01 01:08 [pubmed]
PHST- 2023/07/31 20:42 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - S1470-2118(24)04580-9 [pii]
AID - clinmedicine [pii]
AID - 10.7861/clinmed.2023-0144 [doi]
PST - ppublish
SO  - Clin Med (Lond). 2023 Jul;23(4):337-346. doi: 10.7861/clinmed.2023-0144.